Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).

Literature DB >> 16800982

A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).

Philip M Arlen¹, Mary Pazdur, Lisa Skarupa, Myrna Rauckhorst, James L Gulley.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2006 PMID： 16800982 DOI： 10.3816/CBC.2006.n.032

Source DB: PubMed Journal: Clin Breast Cancer ISSN： 1526-8209 Impact factor: 3.225

Keyword Cloud
Cited

× No keyword cloud information.

22 in total

Review 1. Viral vector-based therapeutic cancer vaccines.

Authors: Cecilia Larocca; Jeffrey Schlom
Journal: Cancer J Date: 2011 Sep-Oct Impact factor: 3.360

Review 2. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

Authors: James W Hodge; Andressa Ardiani; Benedetto Farsaci; Anna R Kwilas; Sofia R Gameiro
Journal: Semin Oncol Date: 2012-06 Impact factor: 4.929

3. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

Authors: Mahsa Mohebtash; Kwong-Yok Tsang; Ravi A Madan; Ngar-Yee Huen; Diane J Poole; Caroline Jochems; Jacquin Jones; Theresa Ferrara; Christopher R Heery; Philip M Arlen; Seth M Steinberg; Mary Pazdur; Myrna Rauckhorst; Elizabeth C Jones; William L Dahut; Jeffrey Schlom; James L Gulley
Journal: Clin Cancer Res Date: 2011-11-08 Impact factor: 12.531

4. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.

Authors: Paul D Bryson; Xiaolu Han; Norman Truong; Pin Wang
Journal: Vaccine Date: 2017-09-12 Impact factor: 3.641

5. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.

Authors: Benedetto Farsaci; Renee N Donahue; Italia Grenga; Lauren M Lepone; Peter S Kim; Brendan Dempsey; Janet C Siebert; Nuhad K Ibrahim; Ravi A Madan; Christopher R Heery; James L Gulley; Jeffrey Schlom
Journal: Cancer Immunol Res Date: 2016-08-02 Impact factor: 11.151

A randomized phase II study of docetaxel alone or in combination with PANVAC-V (vaccinia) and PANVAC-F (fowlpox) in patients with metastatic breast cancer (NCI 05-C-0229).

Review 1. Viral vector-based therapeutic cancer vaccines.

Review 2. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors.

3. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer.

4. Breast cancer vaccines delivered by dendritic cell-targeted lentivectors induce potent antitumor immune responses and protect mice from mammary tumor growth.

5. Analyses of Pretherapy Peripheral Immunoscore and Response to Vaccine Therapy.

Review 6. Vaccinia viruses: vaccines against smallpox and vectors against infectious diseases and tumors.

Review 7. Tecemotide: an antigen-specific cancer immunotherapy.

8. Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts.

Review 9. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference.

Review 10. Combination of physical activity, nutrition, or other metabolic factors and vaccine response.